Red Light Holland announces the purchase of 100 acres of farmland in Ontario that it is targeting for mushroom cultivation.
Exploring the companies and themes that make up this emerging and exciting new sector
How Minera Alamos Turns $20 Of Exploration Spending Into $2,000 Of Gold
From exploration right through to production, Minera Alamos epitomizes efficiency in gold mining.
Red Light Holland Appoints New Chief Marketing Officer
Red Light Holland's new Chief Marketing Officer, Ridley Doolittle, has extensive experience in brand development, including a senior position with Bacardi.
Awakn Successfully Completes Phase One of Its Drug Discovery Program
Awakn Life Sciences announces the completion of its "hit to lead" program on developing new chemical entities (NCE).
Field Trip Health Ltd. Granted US Patent Covering Novel Psychedelic Molecule FT-104
Field Trip announces receiving broad patent protection for its novel molecule, FT-104, from the USPTO.
Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update
Mydecine Innovations reports its financial results for fiscal 2021 and updates investors on the company's R&D.
Delic Expansion Accelerating into 2022 with New Clinic Openings
Delic Holdings announces two new clinics opening through its subsidiary, Ketmine Wellness Centers (KWC).
Novamind Partner to Acquire Specialized Ibogaine Group in Brazil
Novamind is expanding its psychedelics-based therapies into Brazil via its strategic partner in Latin America, Bienstar Wellness Corp.
The Next Big Addiction Treatment
Several psychedelic drugs are touted as effective treatments for drug and alcohol abuse. But psilocybin combined with therapy is emerging as the most effective.
Albert Labs Files US Provisional Patent Application and Proves Out Consistent and Rapidly Scalable Production of Psilocybe and Other Mycelia
Albert Labs announces the filing of a provisional patent application for the production of Psilocybe mycelia and other fungi.
Numinus Completes First MDMA Administration in PTSD Trial Sponsored by MAPS
Numinus announces enrolling the first volunteer patient as it hosts a MAPS clinical trial for an MDMA-assisted treatment for PTSD.